ERYTECH is a clinical-stage biopharmaceutical company that developed innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Founded in Lyon, France in 2004, the company focused on encapsulating therapeutic agents inside red blood cells to reduce toxicity and improve efficacy. ERYTECH was listed on the Nasdaq Capital Market and Euronext Paris. The company later merged with PHERECYDES to form PHAXIAM Therapeutics, which subsequently entered judicial restructuring in 2025.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account